Center-Authored Papers

Filters: Author is Ravandi, Farhad  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E.  2008.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.. Haematologica. 93(8):1263-5.
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.  2008.  Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.. Leukemia research. 32(10):1505-9. Abstract
W
Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR et al..  2010.  Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(10):1766-71. Abstract
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KGM, Ravandi F, Evans A et al..  2013.  Significance of FAB subclassification of "Acute Myeloid Leukemia, NOS" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients.. Blood. Abstract
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH.  2011.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(33):4417-24. Abstract
R
Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM.  2012.  Gemtuzumab ozogamicin: time to resurrect? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(32):3921-3.
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
O
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM et al..  2013.  A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.. British journal of haematology. 163(1):130-2.
O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG et al..  2008.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 6(10):962-93.
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S et al..  2012.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(8):984-1021. Abstract
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE et al..  2017.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(7):926-957. Abstract
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G et al..  2011.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(3):280-317.
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE et al..  2013.  Acute myeloid leukemia, version 2.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(9):1047-55. Abstract
N
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M et al..  2013.  The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.. Frontiers in oncology. 3:218. Abstract
M
Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A.  2011.  Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.. American journal of hematology. 86(9):811-9.
K
Konopleva M, Thall PF, Arana Yi C, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F et al..  2015.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.. Haematologica. Abstract
Kantarjian H, Wilson W, Ravandi F, Estey E.  2013.  Decitabine in older adults with acute myeloid leukemia: why was the dream broken? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(14):1795-6.
B
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
A
Armistead PM, DeLima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R et al..  2009.  Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11):1431-8. Abstract
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S et al..  2017.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.. Blood. 129(10):1275-1283. Abstract